Using DPP-4 inhibitors to modulate beta cell function in type 1 diabetes and in the treatment of diabetic kidney disease / Hugh Davis, Vanessa Jones Briscoe, Sofio Dumbadze, Stephen N. Davis
ABSTRACT Introduction : DPP-4 inhibitors have pleomorphic effects that extend beyond the.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Expert opinion on investigational drugs - 28(2019), 4, Seite 377-388 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Davis, Hugh [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (12 p) |
|---|
| doi: |
10.1080/13543784.2019.1592156 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011199555 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011199555 | ||
| 003 | DE-627 | ||
| 005 | 20230720210236.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230714s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13543784.2019.1592156 |2 doi | |
| 035 | |a (DE-627)KFL011199555 | ||
| 035 | |a (KFL)prod_LgpH_10.1080/13543784.2019.1592156 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Davis, Hugh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Using DPP-4 inhibitors to modulate beta cell function in type 1 diabetes and in the treatment of diabetic kidney disease |c Hugh Davis, Vanessa Jones Briscoe, Sofio Dumbadze, Stephen N. Davis |
| 264 | 1 | |c 2019 | |
| 300 | |a 1 Online-Ressource (12 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Introduction : DPP-4 inhibitors have pleomorphic effects that extend beyond the | ||
| 653 | |a Beta-cell function | ||
| 653 | |a diabetic nephropathy | ||
| 653 | |a dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) | ||
| 653 | |a end stage renal disease (ESRD) | ||
| 653 | |a glucagon-like peptide-1 (GLP-1) | ||
| 653 | |a human | ||
| 653 | |a latent autoimmune diabetes in adult (LADA) | ||
| 653 | |a membrane-bound DPP4 (CD-26) | ||
| 653 | |a rats | ||
| 653 | |a renal disease | ||
| 653 | |a slowly progressive type 1 diabetes (SPIDDM) | ||
| 653 | |a type 1 diabetes (T1DM) | ||
| 653 | |a type 2 diabetes (T2DM) | ||
| 700 | 1 | |a Jones Briscoe, Vanessa |e verfasserin |4 aut | |
| 700 | 1 | |a Dumbadze, Sofio |e verfasserin |4 aut | |
| 700 | 1 | |a Davis, Stephen N. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on investigational drugs |d Abingdon, Oxon : Routledge, Taylor & Francis, 1994 |g 28(2019), 4, Seite 377-388 |h Online-Ressource |w (DE-627)KFL000006041 |w (DE-600)2030114-5 |w (DE-576)302969314 |x 1744-7658 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2019 |g number:4 |g pages:377-388 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/13543784.2019.1592156 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-TFE | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_LgpH_02 | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2019 |e 4 |h 377-388 | ||